Inadequate use of evidence-based doses of ramipril in type 2 diabetic patients with hypertension: HOPE for better results

Practical Diabetes International

Volumn 22, Issue 5, 2005, Pages 161-163

  Jayawarna, C A ^a   Gandhi, R ^a   Thomson, G A ^a   Teliki, R ^a   Lloyd Mostyn, R H ^a   Idris, Iskandar ^a   Fernando, D J S ^a  

^a SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

HOPE study; Hypertension; Ramipril; Type 2 diabetes

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RAMIPRIL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 34447258406     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.797     Document Type: Article

References (13)

1. Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
2. Comparative effects of low and high closes of the angiotensin converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-2318.
3. Jones SC, Bowes PD, Hall E, et al. HOPE for patients with type 2 diabetes: an application of the findings of the MICRO-HOPE substudy in a British hospital diabetes clinic. Diabetic Med 2001; 18: 667-670.
4. Thomson GA. Implementing evidence-based practice. Pract Diabetes Int 2003; 20: 269-270.
5. Ramsay L, Williams B, Johnston G, et al. Guidelines for Management of Hypertension: Report of the third working party of the British Hypertension Society. J Human Hypertens 1999; 13: 569-592.
6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
7. Joseph F, Younis N, Sowery J, et al. Blood pressure control in diabetes: are we achieving guideline targets? Pract Diabetes Int 2003; 20: 276-282.
8. Tight blood pressure control and risk of macro and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.
9. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
10. Agardh CD, Garcia Puig G, Charbonnel B, et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Human Hypertens 1996; 10: 185-192.
11. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38: E28-E32.
12. Heller S. Mistaken priorities in diabetes research. Diabetic Med 2002; 19: 263-264.
13. Perry CG, Kernohan AFB, Petrie JR. Hypertension in diabetes: what's new, what's true, what's next? Pract Diabetes Int 2003; 20: 247-254.